Therapy Areas: AIDS & HIV
Aditxt, Great Lakes Medical Laboratory Launch AditxtScore for COVID-19 in State of Michigan as a Personalized Approach to Addressing COVID-19 Pandemic
12 August 2021 - - US-based biotech innovation company Aditxt, Inc. (NASDAQ: ADTX) has forged a partnership with Midwest, US medical reference laboratory Great Lakes Medical Laboratory, Inc to offer its AditxtScore for COVID-19 throughout the US state of Michigan, the company said.

The AditxtScore for COVID-19 is a more comprehensive immune response monitoring tool that tracks multiple combinations of antibody and neutralizing antibody responses against several different antigens.

This makes it possible to assess the strength of an individual's immune response to the SARS-CoV-2 virus.

Under the agreement, GLML will make the AditxtScore for COVID-19 available throughout its six physical locations and mobile units in Michigan. The initiative is part of Aditxt's ongoing effort to expand its immune monitoring network nationwide.

AditxtScore for COVID-19, which was first introduced in August 2020, differentiates itself from traditional antibody tests by delivering a detailed view of an individual's immune response to multiple antigens associated with COVID-19.

This multiplex approach to capturing the full spectrum of biomarkers associated with COVID-19 delivers a highly detailed snapshot of an individual's immune response in a single test cycle.

It also includes the ability to measure neutralizing antibodies, the subset of virus-specific antibodies that block infection by interfering with cell entry of virus particles.

The level of precision in AditxtScore for COVID-19, along with its ability to measure the neutralizing activity of IgG, IgM and IgA isotopes, can provide clinicians with the data they need to understand the strength and quality of each individual's immune response to COVID-19.

AditxtScore for COVID-19 is offered through authorized channel partners.

Aditxt is developing technologies specifically focused on improving the health of the immune system through immune monitoring and reprogramming. Aditxt's immune monitoring technology is designed to provide a personalized comprehensive profile of the immune system.

Aditxt's immune reprogramming technology is currently at the pre-clinical stage and is designed to retrain the immune system to induce tolerance with an objective of addressing rejection of transplanted organs, autoimmune diseases, and allergies.


Related Headlines